The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a huge mover today! About 872,623 shares traded hands. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has declined 15.65% since April 5, 2016 and is downtrending. It has underperformed by 17.61% the S&P500.
The move comes after 8 months positive chart setup for the $1.15B company. It was reported on Nov, 7 by Barchart.com. We have $12.76 PT which if reached, will make NASDAQ:HALO worth $471.50 million more.
Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on November, 14. They expect $-0.27 EPS, down 42.11% or $0.08 from last year’s $-0.19 per share. After $-0.21 actual EPS reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 28.57% negative EPS growth.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage
Out of 6 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Halozyme Therapeutics has been the topic of 8 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The company was maintained on Friday, September 16 by Piper Jaffray. The rating was initiated by Citigroup on Wednesday, November 18 with “Buy”. The firm earned “Overweight” rating on Wednesday, February 24 by Barclays Capital. JMP Securities maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Tuesday, August 11. JMP Securities has “Market Outperform” rating and $22 price target. The stock has “Overweight” rating given by Barclays Capital on Tuesday, September 22. The firm earned “Buy” rating on Thursday, November 3 by Deutsche Bank.
According to Zacks Investment Research, “Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company’s broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme’s highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in 2016 Q2. Its down 0.29, from 1.33 in 2016Q1. The ratio turned negative, as 21 funds sold all Halozyme Therapeutics, Inc. shares owned while 46 reduced positions. 17 funds bought stakes while 53 increased positions. They now own 103.28 million shares or 2.86% more from 100.41 million shares in 2016Q1.
Stephens Inc Ar holds 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 11,000 shares. Metropolitan Life Ins Communications Ny accumulated 0% or 76,589 shares. State Board Of Administration Of Florida Retirement holds 0% or 91,554 shares in its portfolio. Moreover, Bb Biotech Ag has 2.51% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 7.38M shares. Susquehanna Group Llp reported 31,302 shares or 0% of all its holdings. New York State Common Retirement Fund last reported 382,670 shares in the company. Sit Invest owns 82,350 shares or 0.02% of their US portfolio. Pnc Fincl Grp accumulated 0% or 549 shares. The California-based California Public Employees Retirement System has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Millennium Management Ltd Llc last reported 370,285 shares in the company. Joel Isaacson & Company Lc has invested 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Meeder Asset Mgmt last reported 17,955 shares in the company. Jacobs Levy Equity has 19,100 shares for 0% of their US portfolio. Third Security Ltd Liability Corp holds 8.68% or 19.31M shares in its portfolio. Senzar Asset Mgmt Ltd Llc has invested 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO).
More news for Halozyme Therapeutics, Inc. (NASDAQ:HALO) were recently published by: Fool.com, which released: “Why Halozyme Therapeutics, Inc. Stock Jumped 21.2% in September” on October 10, 2016. Prnewswire.com‘s article titled: “FDA Accepts Genentech’s Biologics License Application For Subcutaneous …” and published on November 03, 2016 is yet another important article.
HALO Company Profile
Halozyme Therapeutics, Inc., incorporated on August 23, 2007, is a biotechnology firm focused on developing and commercializing oncology therapies. The Firm operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. The Company’s research activities focus on human enzymes that alter the extracellular matrix and tumor microenvironment. The Company’s enzymes are used to facilitate the delivery of injected drugs and fluids. The Company’s rHuPH20 is the active ingredient in its commercially approved product, Hylenex recombinant, and it works by temporarily breaking down hyaluronan (HA), a naturally occurring complex carbohydrate that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Firm refers to the application the delivery of other drugs or fluids as its ENHANZE Technology. It licenses the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring injection through the subcutaneous route of administration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.